Skip to content

SemenGlutide: A randomized double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-527538-29-00
Enrollment
150
Registered
2026-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, overweight

Brief summary

Difference in sperm production evaluated by sperm concentration (millions/mL) or total sperm count (millions) at day 200 in Semaglutide- compared to placebo-treated men

Detailed description

Differences in sperm concentration (millions/mL) (day 100, 300) in Semaglutide- compared to placebo-treated men., Differences in DNA fragmentation index (day 300), Changes in DNA fragmentation index (day 200, 300), Changes in sperm parameters (number, motility, morphology) (day 100, 200, 300), Differences in sperm production (sperm concentration, total sperm count, total motile sperm) evaluated by the automated CASA SCA (Microptic) system (baseline and day 200, 300), Differences in body mass index (BMI) and body weight (day 100, 200, 300), Differences in body composition, total body fat percentage, total muscle mass, evaluated by DXA (day 300), Differences in BMD and TBS evaluated by DXA (day 300), Changes in subjective symptoms of androgen deficiency assessed using Androgen Deficiency in the Aging Male questionnaire (ADAM) (day 300), Changes in male sexual function assessed using The International Index of Erectile Function questionnaire (IIEF-5) (day 300), Changes in serum total testosterone (day 100, 200, 300), Differences in free testosterone (day 100, 200, 300), Differences in serum LH and FSH (day 100, 200, 300), Differences in sex hormone binding globulin (SHBG) (day 100, 200, 300), Differences in serum AMH, inhibin B (day 100, 200, 300, Differences in endocrine testicular function (testosterone/LH and inhibin B/FSH ratios) (day 100, 200, 300), Differences in serum estradiol and testosterone/estradiol ratio (day 100, 200, 300), Differences in HbA1c and HOMA-IR (day 100, 200, 300), Differences in total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides (day 100, 200, 300)

Interventions

DRUGNovo Nordisk has made a placebo pen

Sponsors

Region Hovedstaden
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Difference in sperm production evaluated by sperm concentration (millions/mL) or total sperm count (millions) at day 200 in Semaglutide- compared to placebo-treated men

Secondary

MeasureTime frame
Differences in sperm concentration (millions/mL) (day 100, 300) in Semaglutide- compared to placebo-treated men., Differences in DNA fragmentation index (day 300), Changes in DNA fragmentation index (day 200, 300), Changes in sperm parameters (number, motility, morphology) (day 100, 200, 300), Differences in sperm production (sperm concentration, total sperm count, total motile sperm) evaluated by the automated CASA SCA (Microptic) system (baseline and day 200, 300), Differences in body mass index (BMI) and body weight (day 100, 200, 300), Differences in body composition, total body fat percentage, total muscle mass, evaluated by DXA (day 300), Differences in BMD and TBS evaluated by DXA (day 300), Changes in subjective symptoms of androgen deficiency assessed using Androgen Deficiency in the Aging Male questionnaire (ADAM) (day 300), Changes in male sexual function assessed using The International Index of Erectile Function questionnaire (IIEF-5) (day 300), Changes in serum total test

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 9, 2026